XM does not provide services to residents of the United States of America.

Nasdaq, S&P 500 set to open higher ahead of Powell testimony



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Nasdaq, S&P 500 set to open higher ahead of Powell testimony</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.

S&P 500 notches 35th record closing high this year

Powell to speak at 10 a.m. ET

Lilly up after data shows its Mounjaro more efficient than Wegovy

Futures: Dow down 0.01%, S&P 500 up 0.15%, Nasdaq up 0.26%

Updated at 8:43 a.m. ET/1243 GMT

By Lisa Pauline Mattackal and Ankika Biswas

July 9 (Reuters) - Wall Street was set to open higher onTuesday, supported by new gains in semiconductor andmegacap technology stocks,as investors awaited comments fromFederal Reserve chair Jerome Powell for clues on the central bank's monetarypolicy path.

The S&P 500 .SPX and the Nasdaq .IXIC looked on track to set fresh intraday records after both indexes edged upto close at record highs on Monday, lifted by gains in chip stocks and as the Philadelphia semiconductor index .SOX rose to a more than two-week high.

Intel INTC.O shares leapt 2.6% in premarket trading, while AI-chip favorite Nvidia NVDA.O and Marvell Technology MRVL.O gained 1.6% and 0.6%, respectively.

Monday markedthe 35th time this year the S&P 500 hasset a fresh closing record, as sharp gains in AI-linked and other tech shares have kept equity sentiment bright, offsetting the uncertainty around the Fed'srate-cut plans.

Investors will scrutinize Powell'sCongressional testimony later in the day to gauge the central bank's response torecent economic data pointingto a slowdown in the labor market, amid other signs of potential economic weakness.

The testimony, followed by questions from lawmakers, is scheduled to start at 10 a.m. ET. Powell will also testify at a House committee hearing on Wednesday.

"The ability for Powell to change the thinking of the market has been proved over the last six months as the market shifted from six rate cuts to one, and after the weaker data in the last two weeks, back to two," said Bob Savage, head of markets strategy and insights at BNY Mellon.

The last set of economicprojections from the central bank's policymakers showed anexpectation of just one rate cut this year. But markets have stuck to pricing in 50 basis points of easing, seeing a nearly 74% chance for a 25 bps cut at the Fed's September meeting, according to CME's FedWatch.

Those bets were at under50% a month ago.

Meanwhile, rate-sensitive megacap stocks Apple AAPL.O, MicrosoftMSFT.O, Amazon.com AMZN.O, Alphabet GOOGL.O and Meta Platforms META.O were up between 0.1%and 0.4%.

"The market is continuing on a bull run and, with the prospects of rate cuts, I believe may continue for a while," said WisdomTree senior economist Jeremy Siegel.

Crucial inflation data is also due this week, including Thursday'sconsumer price index and the producerprice index reading on Friday.

Investors are also awaitingthe start of the second-quarter corporate earnings season this week. PepsiCo PEP.O edged 0.2% higher ahead of its results on Thursday.

Analysts, on average, see S&P 500 companies increasing their aggregate earnings per share by 10.1% in the second quarter, up from an 8.2% increase in the first quarter, according to LSEG I/B/E/S data.

At 8:43 a.m. ET, Dow e-minis 1YMcv1 were down 4 points, or 0.01%, S&P 500 e-minis EScv1 were up 8.5 points, or 0.15%, and Nasdaq 100 e-minis NQcv1 were up 53 points, or 0.26%.

Among single movers, Tempus AI TEM.O jumped 3.2%after multiple brokerages including J.P.Morgan and Morgan Stanley initiated coverage of the stock with bullish ratings.

Eli Lilly <LLY.N>gained 1.4% aftera data analysis report published on Monday showed its treatment Mounjaro leads to faster and greater weight loss than Novo Nordisk's obesity drug, Wegovy.



Reporting by Lisa Mattackal and Ankika Biswas in Bengaluru; Editing by Pooja Desai

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.